Teva Pharmaceutical Industries Ltd (TEVA)
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
- Symbol
- TEVA
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $46.05B
- 52 week range
- 18.21 - 40.79
Valuation
- Share price
- $39.01 (close of 2026-09-23)
- P/E (TTM)
- 63.74x
- Price to book
- 5.94x
- Price to free cash flow
- 34.19x
- Enterprise value
- $59.27B
- Book value per share
- $6.66
Price performance
| Period | Change |
|---|
| 1 day | -2.62% |
| 5 days | -0.61% |
| 1 month | +4.47% |
| 3 months | +17.46% |
| 6 months | +35.59% |
| Year to date | +24.99% |
| 1 year | +100.57% |
| 3 years | +276.90% |
| 5 years | +331.05% |
| 10 years | -24.21% |
| All time | +4186.82% |
Profitability and growth
- Return on equity
- 17.82%
- Return on invested capital
- 10.06%
- Return on assets
- 3.46%
- Return on capital employed
- 7.90%
- Gross margin
- 51.79%
- Net margin
- 8.17%
- EBITDA margin
- 18.30%
- Revenue growth
- 4.32%
- Net income growth
- 186.03%
- Free cash flow growth
- 53.27%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 2.92%
- Current ratio
- 0.88x
- Net debt to EBITDA
- 5.10x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $17.26B
- Cost of revenue
- $8.32B
- Gross profit
- $8.94B
- EBITDA
- $3.16B
- Net income
- $1.41B
- Earnings per share
- $1.23
- Interest expense
- $916.00M
- Shares outstanding
- 1.15B
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $17.26B | $8.94B | $1.41B | $1.23 |
| 2024-12-31 | $16.54B | $8.06B | $-1.64B | $-1.45 |
| 2023-12-31 | $15.85B | $7.64B | $-559.00M | $-0.50 |
| 2022-12-31 | $14.93B | $6.97B | $-2.45B | $-2.20 |
| 2021-12-31 | $15.88B | $7.59B | $417.00M | $0.38 |
| 2020-12-31 | $16.66B | $7.73B | $-3.99B | $-3.64 |
| 2019-12-31 | $16.89B | $7.54B | $-999.00M | $-0.91 |
| 2018-12-31 | $18.27B | $8.30B | $-2.15B | $-2.35 |
| 2017-12-31 | $21.85B | $10.62B | $-16.27B | $-16.26 |
| 2016-12-31 | $21.90B | $11.65B | $329.00M | $0.07 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 51.79% | 8.17% | 17.82% | 10.06% |
| 2024-12-31 | 48.74% | -9.91% | -30.46% | -1.50% |
| 2023-12-31 | 48.25% | -3.53% | -6.88% | 1.73% |
| 2022-12-31 | 46.72% | -16.39% | -28.45% | -5.68% |
| 2021-12-31 | 47.83% | 2.63% | 3.71% | 13.25% |
| 2020-12-31 | 46.38% | -23.95% | -36.07% | -26.08% |
| 2019-12-31 | 44.63% | -5.92% | -6.63% | -1.36% |
| 2018-12-31 | 45.41% | -11.77% | -13.61% | -8.89% |
| 2017-12-31 | 48.57% | -74.43% | -86.77% | -30.94% |
| 2016-12-31 | 53.20% | 1.50% | 0.94% | 2.34% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $3.56B | - |
| 2024-12-31 | $3.30B | - |
| 2023-12-31 | $3.23B | - |
| 2022-12-31 | $2.80B | - |
| 2021-12-31 | $2.17B | - |
| 2020-12-31 | $2.18B | - |
| 2019-12-31 | $1.98B | - |
| 2018-12-31 | $1.78B | - |
| 2017-12-31 | $963.00M | $28.83B |
| 2016-12-31 | $988.00M | $32.52B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $1.15B | $157.00M |
| 2024-12-31 | $749.00M | $123.00M |
| 2023-12-31 | $842.00M | $121.00M |
| 2022-12-31 | $1.04B | $124.00M |
| 2021-12-31 | $236.00M | $119.00M |
| 2020-12-31 | $638.00M | $129.00M |
| 2019-12-31 | $223.00M | $119.00M |
| 2018-12-31 | $1.79B | $155.00M |
| 2017-12-31 | $1.35B | $133.00M |
| 2016-12-31 | $2.99B | $124.00M |
Dividend history
- Most recent payment
- 2017-11-27
| Payment date | Dividend per share |
|---|
| 2017-11-27 | $0.09 |
| 2017-08-25 | $0.09 |
| 2017-06-01 | $0.34 |
| 2017-02-28 | $0.34 |
| 2016-12-01 | $0.34 |
| 2016-08-18 | $0.34 |
| 2016-05-20 | $0.34 |
| 2016-02-25 | $0.34 |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $0.70
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-29 | Jun/2026 | $0.05 |
| 2026-04-29 | - | - |
| 2026-01-28 | - | - |
| 2025-11-05 | - | - |
| 2025-07-30 | - | - |
| 2025-05-07 | - | - |
| 2025-01-29 | - | - |
| 2024-11-06 | - | - |
Filings and sources
- Company website
- tevapharm.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Zoetis Inc. (ZTS) · Viatris Inc (VTRS) · Hims & Hers Health, Inc. (HIMS) · Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades